Related Experiment Videos
[The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion]
1Pest Megyei Onkormányzat Flór Ferenc Kórháza, Kistarcsa, Neurológiai Osztály.
Insights
Chronic cerebral hypoperfusion causes cognitive impairment and is linked to various dementias. Vinpocetine may benefit these conditions by addressing underlying biochemical and pathophysiological issues.
Area of Science:
- Neurology
- Pathophysiology
Context:
- Cerebrovascular insufficiency, also known as cerebral vascular dysfunction, presents with clinical signs mirroring chronic cerebral hypoperfusion.
- Chronic cerebral hypoperfusion is frequently associated with cognitive impairment and organic psychosyndromes.
- This condition is observed in various dementias, including Binswanger's disease, vascular dementia, and Alzheimer's disease.
Purpose:
- To explore the link between chronic cerebral hypoperfusion and its clinical manifestations.
- To investigate the pathological changes associated with chronic cerebral hypoperfusion, primarily in white matter.
- To elucidate the potential therapeutic role of vinpocetine in managing conditions related to chronic cerebral hypoperfusion.
Summary:
- Clinical symptoms of cerebrovascular insufficiency align with chronic cerebral hypoperfusion, often leading to cognitive deficits and psychosyndromes.
- Pathological hallmarks include white matter changes like demyelination and glial activation, seen across dementias.
- Vinpocetine's mechanism involves modulating multiple biochemical and pathophysiological pathways affected by cerebral hypoperfusion, irrespective of the initial cause.
Impact:
- Understanding the pathophysiology of chronic cerebral hypoperfusion provides a basis for targeted therapeutic interventions.
- Vinpocetine shows promise as a treatment option for cerebrovascular insufficiency by addressing core pathological mechanisms.
- This research may lead to improved management strategies for patients suffering from cognitive decline due to impaired cerebral blood flow.
Abstract:
The clinical signs and symptoms of so-called "cerebrovascular insufficiency" or "cerebral vascular dysfunction" have the characteristics of those of chronic cerebral hypoperfusion. The clinical features of chronic cerebral hypoperfusion often show the symptoms of cognitive impairment and organic psychosyndromes. Cerebral hypoperfusion could be found in dementias of different origin (subcortical arteriosclerotic leucoencephalopathy [Binswanger], vascular dementia, Alzheimer's disease, etc.). Pathological changes caused by chronic cerebral hypoperfusion often confined only to the white matter (demyelisation, glial activation, damage of oligodendroglial cells, as well as scattered cell death). Each therapy has an influence on the biochemical and pathophysiological alterations caused by chronic cerebral hypoperfusion can be used with reason in these disorders. The mechanism of action of vinpocetine is interfering on many aspects with the biochemical and pathophysiological processes attributable to chronic cerebral hypoperfusion, independently of the original alteration responsible for hypoperfusion. This fact might give an explanation on the beneficial effect of vinpocetine on clinical signs and symptoms of chronic cerebrovascular insufficiency.